Helix BioMedix, Inc., a biopharmaceutical company, offers a proprietary library of structurally diverse bioactive peptides and patents covering peptide sequences. Consumer Skin Care Products The company supplies and licenses to skin care contract manufacturers and materials suppliers certain of its proprietary cosmeceutical peptides for inclusion in their acne treatment, anti-aging skin care, color cosmetics, and specialty body care products. The company sells its proprietary skin care products through distributors and directly to consumers. The company’s license agreement with Goldschmidt GmbH, a wholly owned subsidiary of Evonik GmbH (Evonik), a supplier of cosmetic ingredients, provides Evonik with exclusive rights to certain of its peptides targeted towards skin care and personal care applications. Evonik launched a second Helix BioMedix peptide in October 2010 under the name Tego Pep 4-Even. Helix BioMedix Branded Products The company launched its proprietary skin care products under the Striking brand 2008. The product line, which was positioned for the market of perimenopausal and menopausal skin, introduced its exclusive Helix BioMedix SmartPeptide Heptapeptide-7 technology that helps nourish keratinocytes to support skin renewal. The Striking Skin Care line consists of four products: Multi-Vitamin Creme Cleanser, Multi-Peptide Serum, Rejuvenating Eye Creme and Restorative Moisture Creme. The company’s products are distributed through its ecommerce Websites at www.apothederm.com and www.strikingskincare.com, as well as through spas, select catalogues and skin care Internet retailers. In addition, in 2010, the company launched the Cerakine Anti-Aging Skin Care product line, which includes a multi-vitamin cleanser, eye cream, moisturizer and serum that form a core daily cleansing and moisturizing ritual. Helix BioMedix Private Label Products The company supplies private label products to strategic partners with expertise in certain market segments. In 2010, the company entered into a supply agreement with NuGlow Cosmaceuticals, LLC (NuGlow), an affiliated company, for supply of private label products for NuGlow’s direct-to-consumer marketing program. Rx Programs The company develops a topical anti-infective for the treatment of skin and wound infections and the prevention of Staphylococcus aureus (S. aureus) infections including those caused by Methicillin resistant Staphylococcus aureus (MRSA). These programs are based upon a family of molecules known as lipohexapeptides (or small molecule peptides) that the company developed to specifically combine the attributes of small molecule natural products with the advantages of antimicrobial peptides. The company’s topical Rx product development activities are focused on acne anti-infectives, MRSA, and fungal infections. Strategy The company’s business strategy is to develop its peptide and small molecule portfolio to derive revenue from a broad base of opportunities, including licensing rights to third parties to use select proprietary peptides in specific fields of application and commercializing its own branded products. Intellectual Property Rights The company owns or exclusively licenses 10 issued U.S. patents, 5 pending U.S. patent applications, 8 foreign issued patents and 45 foreign pending patent applications. These patents and patent applications describe structures, including alpha-helical, looped, linear, beta-sheet, lipidated, hinged and unstructured short synthetic sequences. In addition, Striking, Cerakine and Apothederm products incorporate various proprietary peptides, which together are protected by claims under U.S. patents expiring between 2021 and 2027. Research and Development As of December 31, 2011, the company’s research and development expenses were approximately $501,000. Regulation The company is subject to regulation by the Occupational Safety & Health Administration (OSHA), and the Environmental Protection Agency (EPA), and to various laws, and regulations relating to safe working conditions, laboratory, and manufacturing practices, and the use, and disposal of hazardous or potentially hazardous substances, including radioactive compounds used in connection with research, and development activities. History Helix BioMedix, Inc. was founded in 1988.
helix biomedix inc (HXBM:OTC US)
22121-17th Avenue SE
Bothell, WA 98021
|No competitor information is available for HXBM.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact HELIX BIOMEDIX INC, please visit www.helixbiomedix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.